Acurx Pharmaceuticals Faces Delisting Concerns
Ticker: ACXP · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1736243
Sentiment: bearish
Topics: delisting, compliance, listing-rule
Related Tickers: ACRX
TL;DR
ACRX might get delisted, stock could be in trouble.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates a potential issue with the company's compliance with stock exchange listing requirements as of February 24, 2025.
Why It Matters
This filing signals potential delisting from a stock exchange, which could significantly impact the liquidity and valuation of Acurx Pharmaceuticals' stock.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- February 24, 2025 (date) — Earliest event reported
- February 26, 2025 (date) — Filing date
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
FAQ
What specific listing rule or standard has Acurx Pharmaceuticals failed to satisfy?
The filing does not specify the exact rule or standard that Acurx Pharmaceuticals has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated February 24, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on February 26, 2025.
What is Acurx Pharmaceuticals' principal executive office address?
The principal executive office is located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the Commission File Number for Acurx Pharmaceuticals?
The Commission File Number for Acurx Pharmaceuticals is 001-40536.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding Acurx Pharmaceuticals, Inc. (ACXP).